Shares of Kamada Ltd. (NASDAQ:KMDA) hit a new 52-week high during trading on Tuesday . The stock traded as high as $4.57 and last traded at $4.56, with a volume of 15,165 shares trading hands. The stock had previously closed at $4.48.

KMDA has been the subject of several research analyst reports. Zacks Investment Research raised shares of Kamada from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research note on Thursday, August 4th. TheStreet raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Monday, April 25th.

The firm’s 50-day moving average is $3.98 and its 200-day moving average is $3.85. The company’s market capitalization is $164.97 million.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The business earned $19.10 million during the quarter, compared to analysts’ expectations of $18.50 million. Equities analysts predict that Kamada Ltd. will post ($0.11) EPS for the current fiscal year.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.